Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Treatment of sarcoidosis -- from a basic science point of view Moller DRJ Intern Med 2003[Jan]; 253 (1): 31-40Progress in our understanding of the scientific basis of granulomatous inflammation in sarcoidosis provides a framework for enlightened treatment decisions. Current evidence supports the concept that the pathogenesis of sarcoidosis involves a highly polarized T-helper 1 (Th1) immune response to pathogenic tissue antigens. Conventional treatment is focused on attenuating granuloma formation with antimalarial drugs that inhibit antigen presentation or with nonspecific anti-inflammatory agents such as glucocorticosteroids, methotrexate, or azathioprine. Anti-tumour necrosis factor (TNF)-alpha agents such as pentoxifylline, thalidomide, etanercept and remicade, have recently shown some successes in sarcoidosis. Designing future therapies depends on improved knowledge of the critical immunological processes operative in different stages of disease.|Etanercept[MESH]|Granuloma/*etiology/immunology[MESH]|Humans[MESH]|Immunoglobulin G/therapeutic use[MESH]|Immunosuppressive Agents/therapeutic use[MESH]|Interleukins/immunology[MESH]|Pentoxifylline/therapeutic use[MESH]|Phosphodiesterase Inhibitors/therapeutic use[MESH]|Receptors, Tumor Necrosis Factor/therapeutic use[MESH]|Sarcoidosis/*drug therapy/immunology[MESH]|Thalidomide/therapeutic use[MESH]|Tumor Necrosis Factor-alpha/antagonists & inhibitors[MESH] |
